NewsBenzingaReported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels Reported Saturday, Lilly Presented First Phase 1 Data For Sofe-M Plus Bevacizumab In Platinum-Sensitive Ovarian Cancer: 79% Confirmed Objective Response Rate, 100% Disease Control Rate, Activity Across FRα Expression Levels Benzinga 2026.10.26 07:12 (GMT+0) Open on Benzinga Other news BMO Capital Initiates Coverage On FirstEnergy with Outperform Rating, Announces Price Target of $50 Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley Weekly Market Pulse: Where The Puck Will Be Amcor’s Quarterly Earnings Preview: What You Need to Know Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
Support for semiconductor stocks could be as much as 15% lower than current levels, says Morgan Stanley
Apple's Design Team Didn't Want Touchscreen Macs, But Tim Cook and John Ternus Had Other Ideas: Report
